Compare ASMB & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | RYAM |
|---|---|---|
| Founded | 2005 | 1926 |
| Country | United States | United States |
| Employees | N/A | 2325 |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 491.8M |
| IPO Year | 2010 | 2014 |
| Metric | ASMB | RYAM |
|---|---|---|
| Price | $28.24 | $11.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.40 | $14.00 |
| AVG Volume (30 Days) | 92.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,466,397,000.00 |
| Revenue This Year | $33.33 | $5.46 |
| Revenue Next Year | N/A | $8.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $3.35 |
| 52 Week High | $39.71 | $11.28 |
| Indicator | ASMB | RYAM |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 69.03 |
| Support Level | $26.50 | $7.09 |
| Resistance Level | $30.66 | N/A |
| Average True Range (ATR) | 1.46 | 0.74 |
| MACD | 0.04 | 0.20 |
| Stochastic Oscillator | 36.74 | 94.92 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.